

DAFTAR PUSTAKA

- Angela M. Auriat , Jason L. Neva , Sue Peters , Jennifer K. Ferris and Lara A. Boyd (2015). A review of transcranial magnetic stimulation and multimodal neuroimaging to characterize post-stroke neuroplasticity. *Frontier in neurology.* published: 29 October 2015 doi: 10.3389/fneur.2015.00226
- Aqueveque P., Ortega P., Pino E., Saavedra F., Germany E., Gómez B. (2017). After stroke movement impairments: a review of current technologies for rehabilitation, in *Physical Disabilities-Therapeutic Implications*, ed Tan U. (London, UK: InTech;), 95–116.
- Bashir S., Mizhari Ilan., Weaver Kayleen., Fregni Felipe., 2010. Assessment and Modulation of Neural Plasticity in Rehabilitation With Transcranial Magnetic Stimulation. *the American Academy of Physical Medicine and Rehabilitation Suppl. 2, S253-S268, December 2010 DOI: 10.1016/j.pmrj.2010.10.015*
- Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics – 2017 update: a report from the American Heart Association. *Circulation* 2017;135:e146-e603
- Bentes C; Peralta A.R; Viana P et al. (2018). Quantitative EEG and functional outcome following acute ischemic stroke. Elsevier. *Clinical Neurophysiology* 129 (2018) 1680-1687
- Bertolucci, F.; Chisari, C.; Fregni, F. The potential dual role of transcallosal inhibition in post-stroke motor recovery. *Restor. Neurol. Neurosci.* 2018, 36, 83–97.
- Bian, Z. et al. (2014) ‘Relative power and coherence of EEG series are related to amnestic mild cognitive impairment in diabetes’, *Frontiers in Aging Neuroscience*, 6(FEB), pp. 1–9. doi: 10.3389/fnagi.2014.00011.
- Bintang, A.K., Akbar, M., Amran, M.Y., Hammado N., 2020. The Effect of High- and Low-Frequency Repetitive Transcranial Magnetic Stimulation Therapy on Serum Brain-Derived Neurotropic Factor Level and Motor Ability in Ischemic Stroke Patients: A Single-Center Study
- Bintang, A.K., Jumraini T., Candra W. 2020. Pengaruh *Repetitive Transcranial Magnetic timulation* terhadap rasio delta theta alfa beta (dtabr) dan Rasio delta alfa (dar) pada korteks motorik Pasien paska stroke iskemik. Program Pendidikan Dokter Spesialis Departemen Neurologi FKUH.

Boehme et al. 2017. Stroke risk factor, genetic, and prevention. American Heart Association. DOI : 10.1161/CIRCRESAHA.116.308398. Departement of epidemiology, Mailman school of public health and departement of Neurolog, college of physician and surgeon. Colombia University.

Brain Stimul, 5 (2012), pp. 526-532, 10.1016/j.brs.2011.07.006.

Braintap. 2018. <https://braintap.com/is-your-brain-working-like-a-symphony-or-a-one-man-band-the-link-between-brain-waves-neurotransmitters-and-mental-wellness/>

Cantero, J. L. et al. (2003) 'Sleep-Dependent θ Oscillations in the Human Hippocampus and Neocortex', *Journal of Neuroscience*, 23(34), pp. 10897–10903. doi: 10.1523/jneurosci.23-34-10897.2003.

Caplan LR. Caplan's Stroke: A Clinical Approach, 4th ed, Saunders Elsevier, Philadelphia: 2016. Basic pathology, anatomy, and pathophysiology of stroke. p. p.22

Carrion J L, Rodriguez JF, Lopez JD, et al. (2009). Delta-alpha ratio correlates with level of recovery after neurorehabilitation in patients with acquired brain injury. *ClinNeurophysiol*; 120(6): 1039–45.

Carmichael, S.T.; Wei, L.; Rovainen, C.M.; Woolsey, T.A. New patterns of intracortical projections after focal cortical stroke. *Neurobiol. Dis.* 2001, 8, 910–922.

Chaturvedi P, Singh A.K, Tiwari V. Diabetes mellitus type 2 impedes functional recovery, neuroplasticity and quality of life after stroke. *J Family Med Prim Care.* 2020 Feb; 9(2): 1035–1041.

Chervyakov, A. V. Chernyavsky, A. Y., Sinitsyn, D. O. & Piradov, M. A. 2015. Possible Mechanisms Underlying the Therapeutic Effects of Transcranial Magnetic Stimulation. *Frontiers in Human Neuroscience*, 9.

Chobanian A. V., Bakris G. L., Black H. R., et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. *The Journal of the American Medical Association*. 2003;289(19):2560–2572. doi: 10.1001/jama.289.19.2560.

Cuspineda E, Machado C, Galan L, et al. (2007) QEEG Prognostic Value in Acute Stroke. *Clinical EEG and Neuroscience.* 2007 Vol 38 No 3.

Di Fillipo, M., Tozzi, A., Costa, C., Belcastro, V., Tantucci, M., Picconi, B. & Calabresi, P. 2008. Plasticity and repair in the post ischemic brain. *Neuropharmacology*, 55, 353-362.

Dionfisio A, Duarte IC, et Al. 2018. The Use of Repetitive Transcranial Magnetic Stimulation for Stroke Rehabilitation: A Systematic Review.

Demos, J. N. (2005) *Getting Started with Neurofeedback*, WW Norton Co. Available at: <http://www.amazon.ca/exec/obidos/redirect?tag=citeulike0920&path=ASIN/0393704505>.

Dubovik S, Pignat JM, Ptak R, Aboulafia T, Allet L, Gillabert N, et al. The behavioral significance of coherent resting-state oscillations after stroke. *Neuroimage* 61:249–57. doi:10.1016/j.neuroimage.2012.03.024

Du Juan, Yang Fang, Hu Jianping et al. Effects of high- and low-frequency repetitive transcranial magnetic stimulation on motor recovery in early stroke patients: Evidence from a randomized controlled trial with clinical, neurophysiological and functional imaging assessments. *Neuroimage clin.* 2019 ; 21: 101620.

Elmasry, M. A., El-LateefMohammad, Z. A., AhmedShehat G., MohammedGhanem H. (2015). Assessment of Musculoskeletal Complications for Immobilized Stroke Patients at Assiut UniversityHospital. *IOSR Journal of Nursing and Health Science (IOSR-JNHS)*, 4, 1-5.

Finnigan S, Michel J.A.M, Putten V. (2012). EEG in ischaemic stroke: Quantitative EEG can uniquely inform (sub-)acute prognoses and clinical management.

Finnigan SP, Walsh M, Rose SE, Chalk JB. Quantitative EEG indices of sub- acute ischaemic stroke correlate with clinical outcomes. *Clin Neurophysiol* (2007) 118:2525–32. doi:10.1016/j.clinph.2007.07.021

Finnigan S, van Putten MJAM. EEG in ischaemic stroke: quantitative EEG can uniquely inform (sub-)acute prognoses and clinical management. *Clin Neurophysiol* 2013;124:10–9.

Fisicaro, F.; Lanza, G.; Grasso, A.A.; Pennisi, G.; Bella, R.; Paulus, W.; Pennisi, M. Repetitive transcranial magnetic stimulation in stroke rehabilitation: Review of the current evidence and pitfalls. *Ther. Adv. Neurol. Disord.* 2019, 12, 1–12.

Gallinat J., Kunz D., Senkowski D., Kienast T., Seifert F., Schubert F., Heinz A. Hippocampal glutamate concentration predicts cerebral θ oscillations

- during cognitive processing. *Psychopharmacology*. 2006;187:103–111. doi: 10.1007/s00213-006-0397-0.
- Gao, B.; Cam, E.; Jaeger, H.; Zunzunegui, C.; Sarnthein, J.; Bassetti, C.L. Sleep disruption aggravates focal cerebral ischemia in the rat. *Sleep* 2010, 33, 879–887.
- Go A.S, Fang M.C, Chang Y, et al. (2014) Long-term survival after ischemic stroke in patients with atrial fibrillation. Available at: <https://n.neurology.org/content/82/12/1033.short>.
- Gomez D, Owens GK. Smooth muscle cell phenotypic switching in atherosclerosis. *Cardiovasc Res*. 2012; 95:156–164. [PubMed: 22406749]
- Gorgoni, M.; D'Atri, A.; Lauri, G.; Rossini, P.M.; Ferlazzo, F.; de Gennaro, L. Is sleep essential for neural plasticity in humans, and how does it affect motor and cognitive recovery? *Neural Plast*. 2013, 2013, 103949, doi:10.1155/2013/103949.
- Giaquinto S, Cobianchi A, Macera F, Nolfe G. EEG recordings in the course of recovery from stroke. *Stroke* (1994) **25**:2204–9. doi:10.1161/01.STR.25.11.2204
- Gudmundsson, S. et al. (2007) ‘Reliability of quantitative EEG features’, *Clinical Neurophysiology*, 118(10), pp. 2162–2171. doi: 10.1016/j.clinph.2007.06.018.
- Gyorgy, B. (2002) ‘Theta oscillations in the hippocampus’, *Neuron*, 33(3), pp. 325–340. Available at: <https://papers3://publication/uuid/90B140FB-AC03-4F7C-9968-EF84D84A3009>.
- Hara, Y. 2015. Brain Plasticity and Rehabilitation in Stroke Patients. *Journal of Nippon Medical School*, 82, 4-13
- He Renhong., Zhong Yuhua, Fan Jianzhong.,et al. Simultaneously stimulating both brain hemispheres by rTMS in patients with unilateral brain lesions. November 2020.
- Iadecola C., Gorelick P. B. Hypertension, Angiotensin, and Stroke: Beyond Blood Pressure. *Stroke*. 2004;35(2):348–350. doi: 10.1161/01.STR.0000115162.16321.AA.
- Ingemanson ML, Rowe JR, Chab V, Eric T, Reinkensmeyer. Somatosensory system integrity explains differences in treatment

response after stroke. American Academy of Neurology. 6 Februari 2019.

Jia, X. and Kohn, A. (2011) 'Gamma rhythms in the brain', *PLoS Biology*, 9(4), pp. 1–5. doi: 10.1371/journal.pbio.1001045.

Jinhong K, Jongeun Y. 2018. Effects of High-Frequency Repetitive Transcranial Magnetic Stimulation Combined with Task-Oriented Mirror Therapy Training on Hand Rehabilitation of Acute Stroke Patients. Medical Science Monitor: Clinical Research. Seoul. 743-750.

Jordan KG. Emergency EEG and continuous EEG monitoring in acute ischemic stroke. *J Clin Neurophysiol* (2004) 21(5):341–52.

Julkunen P, Jauhainen A.M, Kononen M, et al. (2012) Does second-scale intertrial interval affect motor evoked potentials induced by single-pulse transcranial magnetic stimulation?

Katherine herring, Dijk D.J, Dean P, et al (2014). Quantitative Electroencephalography and Behavioural Correlates of Daytime Sleepiness in Chronic Stroke. Hindawi Publishing Corporation BioMed Research International Volume 2014, Article ID 794086, 11 pages <http://dx.doi.org/10.1155/2014/794086>.

Kemenkes. 2018. Laporan Hasil Riset Kesehatan Dasar (Riskesdas) 2018. Badan Penelitian dan Pengembangan Kesehatan Kementerian RI. Jakarta.

Klimesch W (2012). α -band oscillations, attention, and controlled access to stored information. *Trends Cogn Sci*. 2012 Dec; 16(12): 606–617. doi: 10.1016/j.tics.2012.10.007

König IR, Ziegler A, Bluhmki E, et al. Predicting long-term outcome after acute ischemic stroke: a simple index works in patients from controlled clinical trials. *Stroke*. 2008;39:1821.

Lefaucheur *et al.* (2014). *Evidence-Based Guideline on the Therapeutic Use of Repetitive Transcranial Magnetic Stimulation (rTMS)*. *Clinical Neurophysiology*. 125(11): 2150-2206e.

Lewi, P.M.; Thomson, R.H.; Rosenfeld, J.V.; Fitzgerald, P.B. Brain Neuromodulation Techniques: A Review. *Review* 2016, 22, 406–421.

L. J. Volz. 2016. Shaping Early Reorganization of Neural Networks Promotes Motor Function after Stroke. *Cerebral Cortex*, June 2016;26: 2882–2894

Lim S, et al. 2014. Role of vascular smooth muscle cell in the inflammation of atherosclerosis. Yonsei University college of medicine, Seoul. 47(1) : 1-7.

Löfmark U, Hammarström A. Evidence for age-dependent education-related differences in men and women with first-ever stroke. *Neuroepidemiology*. 2007;28:135–41.

Long Hua, Hongbin Wang, Chenguang Zhao. Effects of combining high- and low- frequency repetitive transcranial magnetic stimulation on upper limb hemiparesis in the early phase of stroke. *Restorative Neurology and Neuroscience* 36 (2018) 21–30

Maeda F, et al (2000) Modulation of corticospinal excitability by repetitive transcranial magnetic stimulation

Maher C (2020). Spontaneous Recovery After Stroke: What It Means and How to Encourage It. *Neurological Recovery Blog*.

Matsumoto & Ugawa. (2010). *Transcranial Magnetic Stimulation (TMS) in Clinical Neurology*. Rinsو Shinkeigaku 50. 803- 807.10.5692/clinical neuro. 50.803(pubmed).

Minić GA. Leucocyte count indicates carotid plaque instability in stroke patients. *Vojnosanit Pregl*. 2016 Jun;73(6):515-25.

Morretti J., Eugenia Z., Jennifer Rodger., r-TMS induced change in glutamatnergic and dopaminergic systems : relevance to cocaine and methamphetamine use disorders. *Frontiers in neuroscience*. March 2020.

Moyanova S.G., Dijkhuizen R.M. Present status and future challenges of electroencephalography- and magnetic resonance imaging-based monitoring in preclinical models of focal cerebral ischemia. *Brain Res. Bull.* 2014;102:22–36. doi: 10.1016/j.brainresbull.2014.01.003.

Mu .Z, D. Xiao, J. Hu, 2009, *Classification of Motor Imagery EEG Signals Based on Time-Frequency Analysis*, International Journal of Digital Content Technology and its Application Volume 3, Number 4

Nagata K., Tagawa K., Hiroi S., Shishido F., Uemura K. Electroencephalographic correlates of blood flow and oxygen metabolism provided by positron emission tomography in patients with cerebral infarction. *Electroencephalogr. Clin. Neurophysiol.* 1989;72:16–30. doi: 10.1016/0013-4694(89)90027-8.

Natalia Hackett. (2017). QEEG phenotypes, depression and TMS. Available at: <https://www.progressnp.com/wp-content/uploads/sites/28/2018/08/SR-QEEG-phenotypes-revised-second-proof-lsw.pdf>

Nierhaus, T. et al. (2019) 'Somatosensory Stimulation With XNKQ Acupuncture Modulates Functional Connectivity of Motor Areas', *Frontiers in Neuroscience*, 13(March), pp. 1–8. doi: 10.3389/fnins.2019.00147.

O'Gorman R.L., Poil S.S., Brandeis D., Klaver P., Bollmann S., Ghisleni C., Luchinger R., Martin E., Shankaranarayanan A., Alsop D.C., et al. Coupling between resting cerebral perfusion and EEG. *Brain Topogr.* 2013;26:442–457. doi: 10.1007/s10548-012-0265-7.

Olejniczak P. Neurophysiologic basis of EEG. *J Clin Neurophysiol* (2006) **23**:186–9. doi:10.1097/01.wnp.0000220079.61973.6c

Ossebaard, "Stress reduction by technology? An experimental study into the effects of brainmachines on burnout and state anxiety," *Appl. Psychophysiol. Biofeedback*, 25, No. 2, 93–101 (2000), <https://doi.org/https://doi.org/10.1023/a:1009514824951>.

Ovbiagele, et al. (2013) Forecasting the Future of Stroke in the United States. A Policy Statement From the American Heart Association and American Stroke Association. Available at: <https://www.ahajournals.org/doi/full/10.1161/str.0b013e31829734f2>.

Pellegrino G, Pellegrino G, Tombini M, Assenza G, Bravi M, Sterzi S, et al. Inter-hemispheric coupling changes associate with motor improvements after robotic stroke rehabilitation. *Restor Neurol Neurosci* (2012) **30**:497–510. doi:10.3233/RNN-2012-120227

Palva. New vistas for alpha-frequency band oscillations. Research Gate. May 2007. DOI : 10.1016/j.tins.2007.02.001

POKDI STROKE 2011. Guideline stroke 2011. Jakarta.

Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2018;49:e46-e110.

Qiu Shuang, Wang Sheng Pei, Zhang Chungchen, et al. The lasting effects of 1Hz repetitive transcranial magnetic stimulation on resting state EEG

- in healthy subjects. 2019. Published in : 41 Annual International Conference of the IEEE Engineering in Medicine and Biology Society.
- Ragazzoni, et al. (2013) Vegetative versus minimally conscious states: a study using TMS-EEG, sensory and event-related potentials PLOS ONE, 8 (2013), p. e57069, 10.1371/journal.pone.0057069
- Reddy HP, Jaganath A, et al. A study of age as a risk factor in ischemic stroke of elderly. International Journal of research in Medical sciences, 7(5):1553-1557. 2019. DOI: <http://dx.doi.org/10.18203/2320-6012.ijrms20191634>.
- Sheorajpanday R.V., Nagels G., Weeren A.J., de Surgeloose D., de Deyn P.P. Additional value of quantitative EEG in acute anterior circulation syndrome of presumed ischemic origin. *Clin. Neurophysiol.* 2010;121:1719-1725 doi: 10.1016/j.clinph.2009.10.037.
- Siebner, et al. (2009) Consensus paper: combining transcranial stimulation with neuroimaging Brain Stimul, 2 (2009), pp. 58-80, 10.1016/j.brs.2008.11.002
- Soliman RH, et al. Risk factors of acute ischemic stroke in patients presented to Benisuef University Hospital : prevalence and relation to stroke severity at presentation. 2018; 54(1): 8. doi : 10.1186/s41983-018-0012-4.
- Sporns,et al. (2004) Network attributes for segregation and integration in the human brain Curr. Opin. Neurobiol, 23 (2013), pp. 162-171,10.1016/j.conb.2012.11.015.
- Strafella P. Antonio. (2003). Striatal Dopamine Release Induced by Repetitive Transcranial Magnetic Stimulation of the Human Motor Cortex. Advanced Access Publication August 22, 2003. Brain. Doi: 10.1093/brain/awg268
- Takaeuchi N et al. Noninvasive Brain Stimulation for Motor Recovery after Stroke: Mechanisms and Future Views. September 2012. DOI: 10.1155/2012/584727.
- Teasell R, Hussein N. 2020. Brain reorganization, Recovery and Organized Care. Stroke Rehabilitation Clinical Handbook
- Trujillo P, et al (2017). Quantitative EEG for Predicting Upper-limb Motor Recovery in Chronic Stroke Robot-assisted Rehabilitation. DOI 10.1109/TNSRE.2017.2678161, IEEE Transactions on Neural Systems and Rehabilitation Engineering.

Xu .B.G and A.G. Song, 2008, *Pattern Recognition of Motor Imagery EEG using Wavelet Transform*, J. Biomedica1 Science an Engineering, 1, 64-67, Scientific Reseach.

Yahya N. et al. (2019) Classification of Motor Function from Electroencephalogram (EEG) Signals Based on an Integrated Method Comprised of Common Spatial Pattern and Wavelet Transform Framework. Sensors 2019, 19,4878; doi:10.3390/s19224878.

Yang Ya-Wen et al. Combined effect of repetitive transcranial magnetic stimulation and physical exercise on cortical plasticity. Neural Regeneration Research. doi : 10.4103/1673-5374.282239

Yi, G. S. et al. (2013) 'Modulation of electroencephalograph activity by manual acupuncture stimulation in healthy subjects: An autoregressive spectral analysis', *Chinese Physics B*, 22(2). doi: 10.1088/1674-1056/22/2/028703.

Yuan, Q., Zhou, W., Yuan, S., Li, X., Wang, J., and Jia, G. (2014). Epileptic EEG classification based on kernel sparse representation. *Int. J. Neural Syst.* 24:1450015. doi: 10.1142/S0129065714500154.

Zhang, et al. Effects of repetitive transcranial magnetic stimulation on cognitive function and cholinergic activity in the rat hippocampus after vascular dementia. Oktober 2020.<http://www.nrronline.org>.

Zheng Wei MIng. et al. (2013). Neurogenesis in Adult Human Brain after Traumatic Brain Injury. JOURNAL OF NEUROTRAUMA 30:1872–1880 (November 15, 2013) a Mary Ann Liebert, Inc.DOI: 10.1089/neu.2010.1579.

Zhong Yuhua, Fan J, Wang H, He Renhong (Agustus 2021). Simultaneously stimulating both brain hemispheres by rTMS in patients with unilateral brain lesions decreases interhemispheric asymmetry. Restorative Neurology and Neuroscience xx (2021) x–xx. DOI 10.3233/RNN-211172 IOS Press

Zunzunegui, C.; Gao, B.; Cam, E.; Hodor, A.; Bassetti, C.L. Sleep disturbance impairs stroke recovery in the rat. *Sleep* 2011, 34, 1261–1269.

Lampiran 1. Surat Rekomendasi Etik

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
 UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
 KOMITE ETIK PENELITIAN KESEHATAN
 RSPTN UNIVERSITAS HASANUDDIN
 RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
 Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
 JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
 Contact Person: dr. Agussalim Bukhari.,MMed.,Ph.D.,Sp.GK TELP. 081241850858, 0411 5780103, Fax : 0411-581431



REKOMENDASI PERSETUJUAN ETIK

Nomor : 712/UN4.6.4.5.31/ PP36/ 2021

Tanggal: 9 Nopember 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH21100648	No Sponsor Protokol	
Peneliti Utama	dr. Willy Chandra	Sponsor	
Judul Peneliti	Pengaruh Repetitive Transcranial Magnetic Stimulation Terhadap Perubahan Rasio Delta Theta Alfa Beta (DTABR) dan Fungsi Motorik Pasien Stroke Iskemik		
No Versi Protokol	2	Tanggal Versi	8 Nopember 2021
No Versi PSP	2	Tanggal Versi	8 Nopember 2021
Tempat Penelitian	RS Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input checked="" type="checkbox"/> Fullboard Tanggal 3 Nopember 2021	Masa Berlaku 9 Nopember 2021 sampai 9 Nopember 2022	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH RSUH dan RSWS	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH RSUH dan RSWS	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 2. Instrumen Fugl Mayer Assesment

NASKAH PENJELASAN PADA SUBJEK

Assalamu'alaikumwrwb

Selamat pagi Bapak/Ibu

Perkenalkan saya dr. Willy Candra, dari Departemen Ilmu Penyakit Saraf Fakultas Kedokteran UNHAS. Saya akan melakukan sebuah penelitian sebagai tugas Karya Ilmiah Nasional Program Pendidikan Dokter Spesialis Saraf yang sedang saya jalani berjudul Pengaruh *Repetitive Transcranial Magnetic Stimulation* Terhadap Perubahan Rasio Delta Theta Alfa Beta (DTABR) dan Fungsi Motorik Pasien Stroke Iskemik.

Sebelumnya saya akan menjelaskan tentang hal yang mungkin baru bagi Bapak/Ibu, *Quantitative Electroencephalography (QEEG)* sebagai suatu proses matematika dari data hasil rekaman gelombang otak yang dapat melihat tidak hanya gelombang otak, tinggi gelombang otak, lokasi, tetapi juga dapat mengidentifikasi keselarasan gelombang otak, yaitu tingkat hubungan antar bagian pada otak, fase (kecepatan berpikir) serta kesatuan jaringan. Data yang diperoleh dari QEEG dapat digunakan untuk membuat peta kajian otak atau kode warna dari kerja listrik pada lapisan pembungkus otak. Jika data telah diproses, maka kode warna mewakili nilai normatif. Memahami perubahan gelombang otak yang terjadi karena rangsangan oleh *Transcranial Magnetic Stimulation* sangat penting, karena cara kerja dari *Transcranial Magnetic Stimulation* ini terutama di sistem saraf pusat. *Transcranial Magnetic Stimulation* dan hasil perubahan gelombang otak pada EEG memberikan sumbangsih dalam menjelaskan cara kerja dari efek *Transcranial Magnetic Stimulation* tersebut. Melalui penelitian ini, diharapkan hasilnya dapat menunjukkan pengaruh *Transcranial Magnetic Stimulation* terhadap perubahan gelombang otak yang diukur dengan *Quantitative Electroencephalography* (qEEG). Hasil penelitian diharapkan menjadi informasi untuk masa mendatang dan memberi sumbangsih dalam bidang pendidikan utamanya dalam bidang ilmu penyakit saraf yang saya banggakan dan sedang saya jalani saat ini.

Selanjutnya saya akan menjelaskan prosedur pemeriksaan yang akan dilakukan. Pertama-tama saya mencari orang coba penelitian yang memenuhi kriteria dan apabila Bapak/Ibu setuju untuk terlibat dalam penelitian ini, maka saya akan meminta tanda tangan persetujuan bersedia terlibat dalam penelitian ini. Kemudian akan dilakukan proses perekaman EEG pada Bapak/Ibu selama 5 menit. Persiapan yang harus dilakukan sebelumnya yaitu Bapak/Ibu diminta untuk keramas menggunakan shampo sebelum

dilakukan perekaman EEG. Kemudian Bapak/Ibu akan dibagi menjadi 2 kelompok, kelompok pertama adalah kelompok perlakuan dan kelompok kedua adalah kelompok kontrol. Setelah itu dilakukan rangsangan berupa *Repetitive Transcranial Magnetic Stimulation* sebanyak 10 kali, 5 kali pertama dilakukan secara berturut-turut, kemudia dilakukan jeda 2 hari lalu dilanjutkan lagi sebanyak 5 kali. Pemberian stimulus dilakukan selama 10 menit, pada belahan otak yang mengalami stroke dilakukan pemberian dengan efek merangsang dan pada belahan otak yang tidak mengalami stroke diberikan efek menghambat. Setelah itu ibu/bapak akan direkam lagi menggunakan perekaman EEG yang sama selama 5 menit. Penelitian dilakukan selama 14 hari. Data perekaman tadi akan diproses dengan menggunakan perangkat lunak *NeuroGuide Deluxe qEEG*.

Perekaman ini dianggap aman oleh karena tidak ada perlukaan pada tubuh Bapak/Ibu dan efek samping dari *Transcranial Magnetic Stimulation* ini pun sangat minimal dan bersifat sementara. Sehingga bisa saya katakan bahwa efek samping yang minimal yang dapat terjadi akibat pemeriksaan ini yaitu nyeri saat pemberian stimulus. Pemeriksaan dilakukan dibawah bimbingan dan pengawasan dokter spesialis yang bertanggung jawab.

Selama penelitian, Bapak/ibu tidak dikenakan biaya. Oleh karena prosedur ini adalah sesuai dengan pedoman praktek klinik dan seluruh biaya yang timbul ditanggung oleh peneliti. Saya sebagai peneliti juga akan memberi kompensasi berupa uang transport kepada Bapak/Ibu sebagai wujud terima kasih saya telah bersedia terlibat dalam penelitian ini. Perkiraan waktu yang dibutuhkan dari tanya jawab hingga selesai pemeriksaan ini hanya satu hari dan hanya satu kali pertemuan.

Keikutsertaan Bapak/Ibu dalam penelitian ini bersifat sukarela tanpa paksaan, oleh karena itu apabila dalam perjalannya Bapak/Ibu menolak ikut serta dalam penelitian ini jangan takut akan kehilangan hak untuk mendapatkan pelayanan kesehatan standar rutin.

Data yang dikumpulkan dalam penelitian ini akan disimpan dalam data komputer. Saya akan menjamin kerahasiaan data Bapak/Ibu. Hanya saya sebagai peneliti yang mengetahui data-data Bapak/Ibu.

Sehubungan dengan penelitian ini, bila timbul pertanyaan lebih lanjut diharapkan dapat menghubungi: dr. Willy Candra, nomor telepon: 085350098746.

Identitas Peneliti :

Nama : dr. Willy Candra
Alamat : BTP blok A no 621
Telepon : 085350098746

FORMULIR PERSETUJUAN SETELAH PENJELASAN

Saya yang bertandatangan di bawah ini :

Nama :

Umur :

Alamat :

setelah mendengar/membaca dan mengerti penjelasan yang diberikan mengenai tujuan, manfaat, dan apa yang akan dilakukan pada penelitian ini, menyatakan setuju untuk ikut dalam penelitian ini secara sukarela tanpa paksaan.

Saya tahu bahwa keikutsertaan saya ini bersifat sukarela tanpa paksaan, sehingga saya bisa menolak ikut atau mengundurkan diri dari penelitian ini. Saya berhak bertanya atau meminta penjelasan pada peneliti bila masih ada hal yang belum jelas atau masih ada hal yang ingin saya ketahui tentang penelitian ini.

Saya juga mengerti bahwa semua biaya yang dikeluarkan sehubungan dengan penelitian ini, akan ditanggung oleh peneliti. Saya percaya bahwa keamanan dan kerahasiaan data penelitian akan terjamin dan saya dengan ini menyetujui semua data saya yang dihasilkan pada penelitian ini untuk disajikan dalam bentuk lisan maupun tulisan.

Dengan membubuhkan tandatangan saya di bawah ini, saya menegaskan keikutsertaan saya secara sukarela dalam studi penelitian ini.

Nama	Tanda tangan	Tgl/Bln/Thn
------	--------------	-------------

Responden
.....

/Wali

Saksi
.....

(Tanda Tangan Saksi diperlukan hanya jika Partisipan tidak dapat memberikan consent/persetujuan sehingga menggunakan wali yang sah secara hukum, yaitu untuk partisipan berikut:

1. Usia lanjut
2. Gangguan mental
3. Dan lain-lain kondisi yang tidak memungkinkan memberikan persetujuan

Penanggung Jawab Penelitian	Penanggung Jawab Medis
Nama : dr. Willy Candra	Nama: Dr. dr. Andi Kurnia Bintang Sp.S(K), MARS
Alamat : BTP blok A no.621	Alamat:
Telepon : 085350098746	Telepon: 08114440228

FUGL-MEYER ASSESSMENT
UPPER EXTREMITY (FMA-UE)
Assessment of sensorimotor function

ID:
 Date:
 Examiner:

Fugl-Meyer AR, Jaasko L, Leyman I, Olsson S, Steglind S: The post-stroke hemiplegic patient. A method for evaluation of physical performance. Scand J Rehabil Med 1975; 7:13-31.

A. UPPER EXTREMITY , sitting position		
I. Reflex activity		
Flexors: biceps and finger flexors (at least one)	0	2
Extensors: triceps	0	2
Subtotal I (max 4)		
II. Volitional movement within synergies , without gravitational help		
Flexor synergy: Hand from contralateral knee to ipsilateral ear. From extensor synergy (shoulder adduction/ internal rotation, elbow extension, forearm pronation) to flexor synergy (shoulder abduction/ external rotation, elbow flexion, forearm supination).	Shoulder retraction elevation abduction (90°) external rotation Elbow flexion Forearm supination	0 1 2 0 1 2 0 1 2 0 1 2 0 1 2
Extensor synergy: Hand from ipsilateral ear to the contralateral knee	Shoulder adduction/internal rotation Elbow extension Forearm pronation	0 1 2 0 1 2 0 1 2
Subtotal II (max 18)		
III. Volitional movement mixing synergies , without compensation		
Hand to lumbar spine hand on lap	cannot perform or hand in front of ant-sup iliac spine hand behind ant-sup iliac spine (without compensation) hand to lumbar spine (without compensation)	0 1 2
Shoulder flexion 0°- 90° elbow at 0° pronation-supination 0°	immediate abduction or elbow flexion abduction or elbow flexion during movement flexion 90°, no shoulder abduction or elbow flexion	0 1 2
Pronation-supination elbow at 90° shoulder at 0°	no pronation/supination, starting position impossible limited pronation/supination, maintains starting position full pronation/supination, maintains starting position	0 1 2
Subtotal III (max 6)		
IV. Volitional movement with little or no synergy		
Shoulder abduction 0 - 90° elbow at 0° forearm neutral	immediate supination or elbow flexion supination or elbow flexion during movement abduction 90°, maintains extension and pronation	0 1 2
Shoulder flexion 90° - 180° elbow at 0° pronation-supination 0°	immediate abduction or elbow flexion abduction or elbow flexion during movement flexion 180°, no shoulder abduction or elbow flexion	0 1 2
Pronation/supination elbow at 0° shoulder at 30°- 90° flexion	no pronation/supination, starting position impossible limited pronation/supination, maintains start position full pronation/supination, maintains starting position	0 1 2
Subtotal IV (max 6)		
V. Normal reflex activity assessed only if full score of 6 points is achieved in part IV; compare with the unaffected side		
Biceps, triceps, finger flexors	2 of 3 reflexes markedly hyperactive 1 reflex markedly hyperactive or at least 2 reflexes lively maximum of 1 reflex lively, none hyperactive	0 1 2
Subtotal V (max 2)		
Total A (max 36)		

B. WRIST support may be provided at the elbow to take or hold the starting position, no support at wrist, check the passive range of motion prior testing			none	partial	full
Stability at 15° dorsiflexion elbow at 90°, forearm pronated shoulder at 0°	less than 15° active dorsiflexion dorsiflexion 15°, no resistance tolerated maintains dorsiflexion against resistance	0	1	2	
Repeated dorsiflexion / volar flexion elbow at 90°, forearm pronated shoulder at 0°, slight finger flexion	cannot perform voluntarily limited active range of motion full active range of motion, smoothly	0	1	2	
Stability at 15° dorsiflexion elbow at 0°, forearm pronated slight shoulder flexion/abduction	less than 15° active dorsiflexion dorsiflexion 15°, no resistance tolerated maintains dorsiflexion against resistance	0	1	2	
Repeated dorsiflexion / volar flexion elbow at 0°, forearm pronated slight shoulder flexion/abduction	cannot perform voluntarily limited active range of motion full active range of motion, smoothly	0	1	2	
Circumduction elbow at 90°, forearm pronated shoulder at 0°	cannot perform voluntarily jerky movement or incomplete complete and smooth circumduction	0	1	2	
Total B (max 10)					

C. HAND support may be provided at the elbow to keep 90° flexion, no support at the wrist, compare with unaffected hand, the objects are interposed, active grasp			none	partial	full
Mass flexion from full active or passive extension			0	1	2
Mass extension from full active or passive flexion			0	1	2
GRASP					
a. Hook grasp flexion in PIP and DIP (digits II-V), extension in MCP II-V	cannot be performed can hold position but weak maintains position against resistance	0	1	2	
b. Thumb abduction 1-st CMC, MCP, IP at 0°, scrap of paper between thumb and 2-nd MCP joint	cannot be performed can hold paper but not against tug can hold paper against a tug	0	1	2	
c. Pincer grasp, opposition pulpa of the thumb against the pulpa of 2-nd finger, pencil, tug upward	cannot be performed can hold pencil but not against tug can hold pencil against a tug	0	1	2	
d. Cylinder grasp cylinder shaped object (small can) tug upward, opposition of thumb and fingers	cannot be performed can hold cylinder but not against tug can hold cylinder against a tug	0	1	2	
e. Spherical grasp fingers in abduction/flexion, thumb opposed, tennis ball, tug away	cannot be performed can hold ball but not against tug can hold ball against a tug	0	1	2	
Total C (max 14)					

D. COORDINATION/SPEED , sitting, after one trial with both arms, eyes closed, tip of the index finger from knee to nose, 5 times as fast as possible			marked	slight	none
Tremor			0	1	2
Dysmetria	pronounced or unsystematic slight and systematic no dysmetria	0	1	2	
		≥ 6s	2 - 5s	< 2s	
Time start and end with the hand on the knee	6 or more seconds slower than unaffected side 2-5 seconds slower than unaffected side less than 2 seconds difference	0	1	2	
Total D (max 6)					

TOTAL A-D (max 66)		
---------------------------	--	--

A. UPPER EXTREMITY	/36
B. WRIST	/10
C. HAND	/14
D. COORDINATION / SPEED	/ 6
TOTAL A-D (motor function)	/66

Fugl Mayer Assesment Test Lower Extremity

**FUGL-MEYER ASSESSMENT
LOWER EXTREMITY (FMA-LE)
Assessment of sensorimotor function**

ID:
Date:
Examiner:

Fugl-Meyer AR, Jaasko L, Leyman I, Olsson S, Steglind S: The post-stroke hemiplegic patient. I. a method for evaluation of physical performance. Scand J Rehabil Med 1975, 7:13-31.

E. LOWER EXTREMITY			
I. Reflex activity , supine position		none	can be elicited
Flexors : knee flexors		0	2
Extensors : patellar, achilles (at least one)		0	2
Subtotal I (max 4)			
II. Volitional movement within synergies supine position		none	partial
Flexor synergy : Maximal hip flexion (abduction/external rotation), maximal flexion in knee and ankle joint (palpate distal tendons to ensure active knee flexion).		Hip flexion	0 1 2
		Knee flexion	0 1 2
		Ankle dorsiflexion	0 1 2
Extensor synergy : From flexor synergy to the hip extension/adduction, knee extension and ankle plantar flexion. Resistance is applied to ensure active movement, evaluate both movement and strength (compare with the unaffected side)		Hip extension	0 1 2
		adduction	0 1 2
		Knee extension	0 1 2
		Ankle plantar flexion	0 1 2
Subtotal II (max 14)			
III. Volitional movement mixing synergies sitting position, knee 10cm from the edge of the chair/bed		none	partial
Knee flexion from actively or passively extended knee	no active motion less than 90° active flexion, palpate tendons of hamstrings more than 90° active flexion	0 1	2
Ankle dorsiflexion compare with unaffected side	no active motion limited dorsiflexion complete dorsiflexion	0 1	2
Subtotal III (max 4)			
IV. Volitional movement with little or no synergy standing position, hip at 0°		none	partial
Knee flexion to 90° hip at 0°, balance support is allowed	no active motion or immediate, simultaneous hip flexion less than 90° knee flexion and/or hip flexion during movement at least 90° knee flexion without simultaneous hip flexion	0 1	2
Ankle dorsiflexion compare with unaffected side	no active motion limited dorsiflexion complete dorsiflexion	0 1	2
Subtotal IV (max 4)			
V. Normal reflex activity supine position, assessed only if full score of 4 points is achieved in part IV, compare with the unaffected side		hyper	lively
Reflex activity knee flexors, Patellar, Achilles,	2 of 3 reflexes markedly hyperactive 1 reflex markedly hyperactive or at least 2 reflexes lively maximum of 1 reflex lively, none hyperactive	0 1	2
Subtotal V (max 2)			
Total E (max 28)			

F. COORDINATION/SPEED , supine, after one trial with both legs, eyes closed, heel to knee cap of the opposite leg, 5 times as fast as possible		marked	slight	none
Tremor		0	1	2
Dysmetria	pronounced or unsystematic slight and systematic no dysmetria	0	1	2
		≥ 6s	2 - 5s	< 2s
Time	6 or more seconds slower than unaffected side 2-5 seconds slower than unaffected side less than 2 seconds difference	0	1	2
Total F (max 6)				

E. LOWER EXTERMITY	/28
F. COORDINATION / SPEED	/6
TOTAL E-F (motor function)	/34

Lampiran 3. Data Mentah

Nilai DTABR Pada Kelompok Kontrol

Subyek	Jenis Kelamin	Usia (Tahun)	Onset (hari)	Lesi	Cz		C3		C4		Pz		P3		P4	
					DTABR		DTABR		DTABR		DTABR		DTABR		DTABR	
					Pre	Post										
S01	L	51	17	hemisphere cerebri dextra	0,74	0,80	0,67	0,67	0,95	1,06	0,63	0,56	0,53	0,62	0,87	0,73
S02	P	49	56	hemisphere cerebri sinistra	0,52	0,61	0,57	0,54	1,04	1,24	1,02	1,06	1,00	0,83	1,10	0,85
S03	L	64	15	hemisphere cerebri dextra	0,75	0,74	0,65	0,70	1,02	1,17	0,65	0,64	0,57	0,69	0,83	0,73
S04	L	51	15	hemisphere cerebri sinistra	3,04	2,24	5,18	2,60	3,18	2,48	2,99	2,13	4,29	2,62	3,49	2,15
S05	L	42	21	hemisphere cerebri dextra	1,8	1,81	1,21	1,28	2,66	2,78	1,99	1,99	0,62	1,08	3,29	2,95
S06	P	63	29	hemisphere cerebri sinistra	1,81	1,52	3,93	3,15	1,10	0,88	1,15	0,59	3,02	2,07	0,99	0,51
S07	L	55	20	hemisphere cerebri sinistra	2,50	1,72	2,61	1,74	2,04	1,39	3,22	2,17	2,64	2,13	1,74	0,06
S08	P	44	32	hemisphere cerebri dextra	1,59	1,05	1,16	0,55	1,32	0,94	1,52	0,93	1,02	0,60	1,08	0,62
S09	L	53	15	hemisphere cerebri sinistra	1,04	0,57	0,88	0,59	0,75	0,51	1,12	0,58	1,00	0,63	0,92	0,61
S10	P	59	15	hemisphere cerebri sinistra	1,83	1,76	1,44	1,54	1,22	1,33	2,05	1,96	1,51	1,53	1,93	1,73
S11	L	41	16	hemisphere cerebri dextra	0,40	0,35	0,53	0,46	0,44	0,38	0,37	0,34	0,26	0,24	0,12	0,11
S12	L	54	15	hemisphere cerebri dextra	2,02	2,34	1,29	1,72	2,86	2,82	2,51	2,61	1,36	1,23	3,69	3,56
S13	L	55	30	hemisphere cerebri dextra	1,11	1,13	1,04	0,92	1,86	1,84	1,35	1,20	1,04	0,72	1,50	1,25
S14	L	46	17	hemisphere cerebri dextra	0,64	0,60	0,75	0,70	0,51	0,50	0,60	0,58	0,53	0,52	0,39	0,37
S15	L	52	24	hemisphere cerebri dextra	0,50	0,50	0,50	0,51	0,31	0,31	0,42	0,43	0,42	0,43	0,31	0,30
Mean					1,35	1,18	1,49	1,18	1,42	1,31	1,44	1,18	1,32	1,06	1,48	1,10
SD					0,80	0,66	1,37	0,83	0,90	0,83	0,92	0,77	1,14	0,71	1,15	1,05
Median					1,11	1,05	1,04	0,70	1,10	1,17	1,15	0,93	1,00	0,72	1,08	0,73
Min					0,40	0,35	0,50	0,46	0,31	0,31	0,37	0,34	0,26	0,24	0,12	0,06
Max					3,04	2,34	5,18	3,15	3,18	2,82	3,22	2,61	4,29	2,62	3,69	3,56

Perhitungan selisih skor DTABR pada kelompok kontrol

Subyek	delta_Cz	delta_C3	delta_C4	delta_Pz	delta_P3	delta_P4	delta_DTABRt
1	-0,06	0,00	-0,11	0,07	-0,09	0,14	-0,02
2	-0,09	0,03	-0,20	-0,04	0,17	0,25	0,00
3	0,01	-0,05	-0,15	0,01	-0,12	0,10	-0,12
4	0,80	2,58	0,70	0,86	1,67	1,34	1,55
5	-0,01	-0,07	-0,12	0,00	-0,46	0,34	-0,10
6	0,29	0,78	0,22	0,56	0,95	0,48	0,82
7	0,78	0,87	0,65	1,05	0,51	1,68	0,76
8	0,54	0,61	0,38	0,59	0,42	0,46	0,51
9	0,47	0,29	0,24	0,54	0,37	0,31	0,24
10	0,07	-0,10	-0,11	0,09	-0,02	0,20	0,06
11	0,05	0,07	0,06	0,03	0,02	0,01	0,04
12	-0,32	-0,43	0,04	-0,10	0,13	0,13	-0,12
13	-0,02	0,12	0,02	0,15	0,32	0,25	0,22
14	0,04	0,05	0,01	0,02	0,01	0,02	0,01
15	0,00	-0,01	0,00	-0,01	-0,01	0,01	0,01
Mean	0,17	0,32	0,11	0,25	0,26	0,38	0,26
SD	0,33	0,72	0,28	0,37	0,51	0,49	0,47
median	0,04	0,05	0,02	0,07	0,13	0,25	0,04
Min	-0,32	-0,43	-0,20	-0,10	-0,46	0,01	-0,12
Max	0,80	2,58	0,70	1,05	1,67	1,68	1,55

Skor FMA Pada Kelompok Kontrol

Subyek	Jenis Kelamin	Usia (Tahun)	Skor FMA		FMA UE		FMA LE		delta FMA	Letak Lesi
			Pre	Post	PRE	POST	PRE	POST		
S01	L	51	79	84	52	55	27	29	5	infark lobus frontal dextra
S02	P	49	8	20	4	13	4	7	12	infark nukleas caudatus dan capsula externa sinistra
S03	L	64	54	56	42	43	12	13	2	corona radiata dextra
S04	L	51	11	32	6	22	5	10	21	infark corona radiata, capsula interna, capsula eksterna nucleus lentiformis dan lobus frotalis sinistra
S05	L	42	9	15	4	6	5	9	6	infark luas lobus frontotemporoparietal dextra
S06	P	63	8	24	4	14	4	10	16	infark corona radiata sinistra
S07	L	55	37	55	28	39	9	16	18	infark corona radiata sinistra, ganglia basalis sinistra
S08	P	44	53	72	39	50	14	22	19	infark lobus parietal dextra
S09	L	53	51	70	38	52	13	18	19	corona radiata sinistra
S10	P	59	41	48	29	31	12	17	7	capsula interna sinistra
S11	L	41	55	67	38	45	17	22	12	infark dextra
S12	L	54	27	47	21	33	6	14	20	infark corona radiata dextra
S13	L	55	50	72	35	51	15	21	22	infark corona radiata dan capsula interna dextra
S14	L	46	37	58	27	43	10	15	21	infark nuclei basal dextra
S15	L	52	71	78	53	55	18	23	7	infark frontal dextra
Mean			39,40	53,20	28,00	36,80	11,40	16,40	13,80	
SD			22,87	21,89	16,97	16,30	6,38	6,17	6,88	
Median			41,00	56,00	29,00	43,00	12,00	16,00	16,00	
Min			8,00	15,00	4,00	6,00	4,00	7,00	2,00	
Max			79,00	84,00	53,00	55,00	27,00	29,00	22,00	

Nilai DTABR Pada Kelompok Perlakuan

Subyek	Jenis Kelamin	Usia (Tahun)	Onset (hari)	Lesi	Cz		C3		C4		Pz		P3		P4	
					DTABR		DTABR		DTABR		DTABR		DTABR		DTABR	
					Pre	Post										
S01	P	59	16	hemisphere cerebri sinistra	0,33	0,32	0,30	0,26	0,30	0,32	0,29	0,29	0,29	0,26	0,28	0,28
S02	L	41	56	hemisphere cerebri dextra	2,04	1,69	2,19	1,37	2,38	1,68	1,76	1,30	1,86	1,09	1,61	1,12
S03	L	60	15	hemisphere cerebri dextra	3,60	1,34	1,89	0,87	3,24	1,50	3,45	1,50	2,24	1,10	4,58	2,07
S04	L	40	25	hemisphere cerebri dextra	3,84	2,57	3,60	1,94	3,64	2,59	2,48	1,91	2,40	1,14	3,06	2,74
S05	L	51	15	hemisphere cerebri dextra	1,09	1,15	0,98	0,89	1,01	0,58	1,21	0,96	1,03	0,85	1,03	0,81
S06	L	40	78	hemisphere cerebri dextra	2,89	2,71	3,62	2,76	1,83	1,70	2,89	2,13	3,72	2,27	1,94	1,56
S07	L	48	15	hemisphere cerebri dextra	1,39	1,31	1,80	1,80	0,98	0,75	1,74	0,92	2,12	2,49	1,16	0,26
S08	P	55	21	hemisphere cerebri sinistra	2,30	1,69	2,47	1,78	2,00	0,99	2,04	1,10	2,16	2,75	1,69	1,60
S09	L	52	15	hemisphere cerebri dextra	1,98	1,73	1,81	1,96	1,35	1,43	1,83	1,67	1,79	1,70	1,31	1,31
S10	L	48	22	Hemisphere cerebri dextra	5,87	2,46	6,17	2,39	5,88	2,42	5,38	2,21	4,46	2,20	5,61	2,27
S11	L	65	32	Hemisphere cerebri dextra	1,43	1,10	2,64	1,39	2,35	1,21	3,00	1,22	1,16	1,24	1,34	1,32
S12	L	60	15	Hemisphere cerebri sinistra	7,11	1,57	10,03	1,66	6,17	1,15	7,81	1,72	10,24	2,06	5,95	1,45
S13	P	48	87	Hemisphere cerebri dextra	5,87	2,46	6,17	2,39	5,88	2,42	5,38	2,21	4,46	2,20	5,61	2,27
S14	L	62	34	Hemisphere cerebri sinistra	0,85	0,50	0,71	0,51	0,89	0,53	0,95	0,60	0,91	0,51	0,91	0,58
S15	P	56	17	Hemisphere cerebri sinistra	1,14	0,27	1,06	0,24	1,03	0,19	0,91	0,45	0,79	0,27	0,92	0,35
Mean					2,78	1,52	3,03	1,48	2,60	1,30	2,74	1,35	2,64	1,48	2,47	1,33
SD					2,07	0,79	2,62	0,79	1,97	0,77	2,04	0,63	2,45	0,82	1,97	0,78
Median					2,04	1,57	2,19	1,66	2,00	1,21	2,04	1,30	2,12	1,24	1,61	1,32
Min					0,33	0,27	0,30	0,24	0,30	0,19	0,29	0,29	0,29	0,26	0,28	0,26
Max					7,11	2,71	10,03	2,76	6,17	2,59	7,81	2,21	10,24	2,75	5,95	2,74

Perhitungan selisih skor DTABR pada kelompok perlakuan

Subyek	delta_Cz	delta_C3	delta_C4	delta_Pz	delta_P3	delta_P4	delta_DTABRt
1	0,01	0,04	-0,02	0,00	0,03	0,00	0,20
2	0,35	0,82	0,70	0,46	0,77	0,49	0,66
3	2,26	1,02	1,74	1,95	1,14	2,51	1,99
4	1,27	1,66	1,05	0,57	1,26	0,32	0,92
5	-0,06	0,09	0,43	0,25	0,18	0,22	0,45
6	0,18	0,86	0,13	0,76	1,45	0,38	0,14
7	0,08	0,00	0,23	0,82	-0,37	0,90	0,32
8	0,61	0,69	1,01	0,94	-0,59	0,09	0,77
9	0,25	-0,15	-0,08	0,16	0,09	0,00	0,18
10	3,41	3,78	3,46	3,17	2,26	3,34	3,36
11	0,33	1,25	1,14	1,78	-0,08	0,02	0,56
12	5,54	8,37	5,02	6,09	8,18	4,50	7,12
13	3,41	3,78	3,46	3,17	2,26	3,34	2,36
14	0,35	0,20	0,36	0,35	0,40	0,33	0,29
15	0,87	0,82	0,84	0,46	0,52	0,57	0,54
Mean	1,26	1,55	1,30	1,40	1,17	1,13	1,32
SD	1,66	2,25	1,51	1,65	2,13	1,50	1,85
median	0,35	0,82	0,84	0,76	0,52	0,38	0,56
Min	-0,06	-0,15	-0,08	0,00	-0,59	0,00	0,14
Max	5,54	8,37	5,02	6,09	8,18	4,50	7,12

Skor FMA Pada Kelompok Perlakuan

Subyek	Skor FMA		FMA UE		FMA LE		delta_FMA	Letak Lesi
	Pre	Post	PRE	POST	PRE	POST		
S01	53	88	40	62	13	26	35	infark lacunar corona radiata sinistra
S02	29	50	23	39	6	11	21	infark corona radiata dextra
S03	8	37	4	20	4	17	29	infark nuclei basal dextra
S04	8	36	4	16	4	20	28	infark luas lobus frontotemporoparietal dextra
S05	28	62	21	43	7	19	34	infark cerebri parahippocampal gyrus dextra
S06	8	29	4	15	4	14	21	infark cerebri lobus temporoparietooccipital dextra
S07	39	63	30	44	9	19	24	infark luas temporal dextra
S08	50	81	36	58	14	23	31	corona radiata kapsula interna dan thalamus sinistra
S09	55	79	43	53	12	26	24	infark capsula interna dextra
S10	52	74	37	53	15	21	22	infark lobus frontal dextra
S11	49	72	37	50	12	22	23	corona radiata sinistra
S12	45	71	32	53	13	18	26	Infark luas pada frontotemporoparietal sinistra
S13	31	65	23	47	8	18	34	corona radiata dextra
S14	50	74	37	53	13	21	24	infark nukleus caudatus dan capsula externa sinistra
S15	63	82	48	58	15	24	19	capsula interna sinistra
Mean	37,87	64,20	27,93	44,27	9,93	19,93	26,33	
SD	18,37	18,26	14,45	15,38	4,13	4,13	5,22	
Median	45,00	71,00	32,00	50,00	12,00	20,00	24,00	
Min	8,00	29,00	4,00	15,00	4,00	11,00	19,00	
Max	63,00	88,00	48,00	62,00	15,00	26,00	35,00	

Nilai Persentase Total Gelombang Otak Pada Kelompok Perlakuan

Kelompok	Subyek	Sebelum				Setelah				DTABR	
		Delta	Theta	Alfa	Beta	Delta	Theta	Alfa	Beta	Sebelum	Setelah
Perlakuan	1	21,2	13,9	47,1	17,8	14,2	11	52,4	22,4	0,54	0,34
	2	36,6	31,9	15,2	16,3	29,8	30,5	28,2	11,5	2,17	1,52
	3	60,3	15,2	8,5	16	35,4	16,7	14	33,9	3,08	1,09
	4	50,4	27,2	11,2	11,2	41	30,7	11,6	16,6	3,46	2,54
	5	34,4	21,2	28,9	15,5	21,2	23,2	31,7	23,9	1,25	0,80
	6	52,3	16,6	13,3	17,8	46,9	20,6	11,7	20,8	2,22	2,08
	7	37,3	20,5	19	23,2	33,3	18	31,2	17,5	1,37	1,05
	8	38,1	33,4	21	7,5	27,9	35,6	28	8,5	2,51	1,74
	9	45,3	24,3	16,6	13,8	39	28,8	18,6	13,6	2,29	2,11
	10	74,5	9,2	7,8	8,5	52	12	19,8	16,2	5,13	1,78
	11	55,1	8,2	25,6	11,1	37,5	16,2	25,3	21	1,72	1,16
	12	71,3	18,4	5	5,2	44,4	18,2	12,3	25,1	8,79	1,67
	13	70,7	11,4	9,3	8,6	48,5	20,5	12	19	4,59	2,23
	14	35,5	15	23,5	26	23,8	18,5	28,7	29	1,02	0,73
	15	37,3	17	31,3	14,4	18	21,2	40,1	20,7	1,19	0,64
Mean										2,76	1,43
SD										2,11	0,66
Median										2,22	1,52
Min										0,54	0,34
Max										8,79	2,54

Nilai Persentase Total Gelombang Otak Pada Kelompok Kontrol

Kelompok	Subyek	Sebelum				Setelah				DTABR	
		Delta	Theta	Alfa	Beta	Delta	Theta	Alfa	Beta	Sebelum	Setelah
Kontrol	1	18,7	27	42,2	12,1	18,4	28	42,8	10,8	0,84	0,87
	2	22,6	25,6	37,2	14,6	21,8	26,3	37,3	14,6	0,93	0,93
	3	21,5	24,1	46,4	8	16,3	32,6	43,7	7,4	0,84	0,96
	4	51,2	28,4	11,6	8,8	37	33,2	16,2	13,6	3,90	2,36
	5	47,6	19	26,2	7,2	38,9	28,8	21,6	10,7	1,99	2,10
	6	47,5	22	16,2	14,3	31,5	27,8	29,3	11,4	2,28	1,46
	7	41,7	25,5	15	17,8	33,8	22,6	23,6	20	2,05	1,29
	8	30,5	24,4	26,2	18,9	18,5	22,8	34	24,7	1,22	0,70
	9	25,5	25,2	17,6	31,7	25,5	18,7	20,5	35,3	1,03	0,79
	10	41,7	23,5	20,5	14,3	42,7	21,8	19,6	15,9	1,87	1,82
	11	19,4	10,8	60,3	9,5	17,6	10,5	62,1	9,8	0,43	0,39
	12	31,6	37,1	22,2	9,1	31,7	38,1	22,3	7,9	2,19	2,31
	13	21,5	36	30,2	12,3	19,9	33,3	34,4	12,4	1,35	1,14
	14	14,2	23,7	52,8	9,3	14,4	23	53,1	9,5	0,61	0,60
	15	14,7	16,5	54	14,8	14,6	16,3	54,4	14,7	0,45	0,45
Mean									1,47	1,21	
SD									0,93	0,66	
Median									1,22	0,96	
Min									0,43	0,39	
Max									3,90	2,36	

Lampiran 4. Deskripsi Statistik

Frequency Table

Usia Kontrol					
	Frequency	Percent	Valid Percent	Cumulative Percent	
Valid	41.00	1	6.7	6.7	6.7
	42.00	1	6.7	6.7	13.3
	44.00	1	6.7	6.7	20.0
	46.00	1	6.7	6.7	26.7
	49.00	1	6.7	6.7	33.3
	51.00	2	13.3	13.3	46.7
	52.00	1	6.7	6.7	53.3
	53.00	1	6.7	6.7	60.0
	54.00	1	6.7	6.7	66.7
	55.00	2	13.3	13.3	80.0
	59.00	1	6.7	6.7	86.7
	63.00	1	6.7	6.7	93.3
	64.00	1	6.7	6.7	100.0
Total		15	100.0	100.0	

Jenis Kelamin

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Laki-laki	11	73.3	73.3
	Perempuan	4	26.7	100.0
	Total	15	100.0	100.0

Jenis kelamin Kontrol

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Laki-laki	11	73.3	73.3
	Perempuan	4	26.7	100.0
	Total	15	100.0	100.0

Hipertensi

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Ya	9	60.0	60.0	60.0
Tidak	6	40.0	40.0	100.0
Total	15	100.0	100.0	

Hipertensi kontrol

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Ya	11	73.3	73.3	73.3
Tidak	4	26.7	26.7	100.0
Total	15	100.0	100.0	

Diabetes Mellitus

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Tidak	15	100.0	100.0	100.0

Diabetes Mellitus kontrol

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Tidak	15	100.0	100.0	100.0

HT + DM

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Ya	6	40.0	40.0	40.0
Tidak	9	60.0	60.0	100.0
Total	15	100.0	100.0	

HT + DM kontrol

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Ya	4	26.7	26.7	26.7
Tidak	11	73.3	73.3	100.0
Total	15	100.0	100.0	

Onset Stroke

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid 15.00	5	33.3	33.3	33.3
16.00	1	6.7	6.7	40.0

17.00	1	6.7	6.7	46.7
21.00	1	6.7	6.7	53.3
22.00	1	6.7	6.7	60.0
25.00	1	6.7	6.7	66.7
32.00	1	6.7	6.7	73.3
34.00	1	6.7	6.7	80.0
56.00	1	6.7	6.7	86.7
78.00	1	6.7	6.7	93.3
87.00	1	6.7	6.7	100.0
Total	15	100.0	100.0	

Onset Stroke					
	Frequency	Percent	Valid Percent	Cumulative Percent	
Valid	15.00	5	33.3	33.3	33.3
	16.00	1	6.7	6.7	40.0
	17.00	2	13.3	13.3	53.3
	20.00	1	6.7	6.7	60.0
	21.00	1	6.7	6.7	66.7
	24.00	1	6.7	6.7	73.3
	29.00	1	6.7	6.7	80.0
	30.00	1	6.7	6.7	86.7
	32.00	1	6.7	6.7	93.3
	56.00	1	6.7	6.7	100.0
Total	15	100.0	100.0		

FMA pre					
	Frequency	Percent	Valid Percent	Cumulative Percent	
Valid	8.00	3	20.0	20.0	20.0
	28.00	1	6.7	6.7	26.7
	29.00	1	6.7	6.7	33.3
	31.00	1	6.7	6.7	40.0
	39.00	1	6.7	6.7	46.7
	45.00	1	6.7	6.7	53.3
	49.00	1	6.7	6.7	60.0
	50.00	2	13.3	13.3	73.3
	52.00	1	6.7	6.7	80.0
	53.00	1	6.7	6.7	86.7

55.00	1	6.7	6.7	93.3
63.00	1	6.7	6.7	100.0
Total	15	100.0	100.0	

FMA pre kontrol

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid	8.00	2	13.3	13.3
	9.00	1	6.7	20.0
	11.00	1	6.7	26.7
	27.00	1	6.7	33.3
	37.00	2	13.3	46.7
	41.00	1	6.7	53.3
	50.00	1	6.7	60.0
	51.00	1	6.7	66.7
	53.00	1	6.7	73.3
	54.00	1	6.7	80.0
	55.00	1	6.7	86.7
	71.00	1	6.7	93.3
	79.00	1	6.7	100.0
Total		15	100.0	100.0

FMA post

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid	29.00	1	6.7	6.7
	36.00	1	6.7	13.3
	37.00	1	6.7	20.0
	50.00	1	6.7	26.7
	62.00	1	6.7	33.3
	63.00	1	6.7	40.0
	65.00	1	6.7	46.7
	71.00	1	6.7	53.3
	72.00	1	6.7	60.0
	74.00	2	13.3	73.3
	79.00	1	6.7	80.0
	81.00	1	6.7	86.7
	82.00	1	6.7	93.3
	88.00	1	6.7	100.0

Total	15	100.0	100.0
-------	----	-------	-------

FMA post kontrol

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid	15.00	1	6.7	6.7
	20.00	1	6.7	13.3
	24.00	1	6.7	20.0
	32.00	1	6.7	26.7
	47.00	1	6.7	33.3
	48.00	1	6.7	40.0
	55.00	1	6.7	46.7
	56.00	1	6.7	53.3
	58.00	1	6.7	60.0
	67.00	1	6.7	66.7
	70.00	1	6.7	73.3
	72.00	2	13.3	86.7
	78.00	1	6.7	93.3
	84.00	1	6.7	100.0
Total	15	100.0	100.0	

Lokasi Lesi

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Hemisfer Dextra	10	66.7	66.7
	Hemisfer Sinistra	5	33.3	100.0
Total		15	100.0	100.0

Lokasi Lesi kontrol

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Hemisfer Dextra	9	60.0	60.0
	Hemisfer Sinistra	6	40.0	100.0
Total		15	100.0	100.0

Usia

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid	36-45 tahun	3	20.0	20.0
	46-55 tahun	6	40.0	60.0
	56-65 tahun	6	40.0	100.0

Total	15	100.0	100.0	
-------	----	-------	-------	--

Usia kontrol

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid	36-45 tahun	3	20.0	20.0
	46-55 tahun	9	60.0	80.0
	56-65 tahun	3	20.0	100.0
Total		15	100.0	100.0

Crosstabs

Case Processing Summary

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
JK * Kelompok	30	100.0%	0	0.0%	30	100.0%
Usia * Kelompok	30	100.0%	0	0.0%	30	100.0%
Onset * Kelompok	30	100.0%	0	0.0%	30	100.0%
Lesi * Kelompok	30	100.0%	0	0.0%	30	100.0%

JK * Kelompok

Crosstab

		Kelompok		Total
		Perlakuan	Kontrol	
JK	L	Count	11	22
		% within Kelompok	73.3%	73.3%
		% of Total	36.7%	36.7%
	P	Count	4	8
		% within Kelompok	26.7%	26.7%
		% of Total	13.3%	13.3%
Total		Count	15	30
		% within Kelompok	100.0%	100.0%
		% of Total	50.0%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.000 ^a	1		1.000	
Continuity Correction ^b	.000	1		1.000	
Likelihood Ratio	.000	1		1.000	
Fisher's Exact Test				1.000	.659
N of Valid Cases	30				

a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 4.00.

b. Computed only for a 2x2 table

Symmetric Measures^a

	Value
N of Valid Cases	30

a. Correlation statistics are available for numeric data only.

Usia * Kelompok

Crosstab

		Kelompok		Total
		Perlakuan	Kontrol	
Usia	Count	3	3	6
	% within Kelompok	20.0%	20.0%	20.0%
	% of Total	10.0%	10.0%	20.0%
	Count	3	2	5
	% within Kelompok	20.0%	13.3%	16.7%
	% of Total	10.0%	6.7%	16.7%
	Count	2	5	7
	% within Kelompok	13.3%	33.3%	23.3%
	% of Total	6.7%	16.7%	23.3%
	Count	3	3	6
	% within Kelompok	20.0%	20.0%	20.0%
	% of Total	10.0%	10.0%	20.0%
55 - 59 tahun	Count	3	2	5
	% within Kelompok	20.0%	13.3%	16.7%
	% of Total	10.0%	6.7%	16.7%
60 - 64 tahun	Count	1	0	1
	% within Kelompok	6.7%	0.0%	3.3%
	% of Total	3.3%	0.0%	3.3%
65 tahun ke atas	Count	15	15	30
	% within Kelompok	100.0%	100.0%	100.0%
	% of Total	50.0%	50.0%	100.0%
Total				

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)
Pearson Chi-Square	2.686 ^a	5	.748
Likelihood Ratio	3.117	5	.682
Linear-by-Linear Association	.242	1	.623
N of Valid Cases	30		

a. 12 cells (100.0%) have expected count less than 5. The minimum expected count is .50.

Symmetric Measures

		Value	Asymp. Std. Error ^a	Approx. T ^b	Approx. Sig.
Interval by Interval	Pearson's R	-.091	.180	-.486	.631 ^c
Ordinal by Ordinal	Spearman Correlation	-.082	.184	-.438	.665 ^c
N of Valid Cases		30			

a. Not assuming the null hypothesis.

b. Using the asymptotic standard error assuming the null hypothesis.

c. Based on normal approximation.

Onset * Kelompok

Crosstab

		Kelompok		Total
		Perlakuan	Kontrol	
Onset	< = 20 hari	Count	7	9
		% within Kelompok	46.7%	60.0%
		% of Total	23.3%	30.0%
	> 20 hari	Count	8	6
		% within Kelompok	53.3%	40.0%
		% of Total	26.7%	20.0%
Total		Count	15	15
		% within Kelompok	100.0%	100.0%
		% of Total	50.0%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.536 ^a	1	.464		
Continuity Correction ^b	.134	1	.714		
Likelihood Ratio	.537	1	.464		
Fisher's Exact Test				.715	.358
Linear-by-Linear Association	.518	1	.472		
N of Valid Cases	30				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 7.00.

b. Computed only for a 2x2 table

Symmetric Measures

		Value	Asymp. Std. Error ^a	Approx. T ^b	Approx. Sig.
Interval by Interval	Pearson's R	-.134	.181	-.714	.481 ^c
Ordinal by Ordinal	Spearman Correlation	-.134	.181	-.714	.481 ^c
N of Valid Cases		30			

a. Not assuming the null hypothesis.

b. Using the asymptotic standard error assuming the null hypothesis.

c. Based on normal approximation.

Lesi * Kelompok

Crosstab

		Kelompok		Total
		Perlakuan	Kontrol	
Lesi	Hemisphere cerebri dextra	Count	10	19
		% within Kelompok	66.7%	63.3%
		% of Total	33.3%	30.0%
	Hemisphere cerebri sinistra	Count	5	11
		% within Kelompok	33.3%	36.7%
		% of Total	16.7%	20.0%
	Total	Count	15	30
		% within Kelompok	100.0%	100.0%
		% of Total	50.0%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.144 ^a	1	.705		
Continuity Correction ^b	.000	1	1.000		
Likelihood Ratio	.144	1	.705		
Fisher's Exact Test				1.000	.500
N of Valid Cases	30				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 5.50.

b. Computed only for a 2x2 table

Symmetric Measures^a

	Value
N of Valid Cases	30

a. Correlation statistics are available for numeric data only.

Deskriptif DTABR dan FMA

Means

Case Processing Summary

	Cases					
	Included		Excluded		Total	
	N	Percent	N	Percent	N	Percent
Cz_Pre * Kelompok	30	100.0%	0	0.0%	30	100.0%
Cz_Post * Kelompok	30	100.0%	0	0.0%	30	100.0%
C3_Pre * Kelompok	30	100.0%	0	0.0%	30	100.0%
C3_Post * Kelompok	30	100.0%	0	0.0%	30	100.0%
C4_Pre * Kelompok	30	100.0%	0	0.0%	30	100.0%
C4_Post * Kelompok	30	100.0%	0	0.0%	30	100.0%
Pz_Pre * Kelompok	30	100.0%	0	0.0%	30	100.0%
Pz_Post * Kelompok	30	100.0%	0	0.0%	30	100.0%
P3_Post * Kelompok	30	100.0%	0	0.0%	30	100.0%
P3_Pre * Kelompok	30	100.0%	0	0.0%	30	100.0%
P4_Pre * Kelompok	30	100.0%	0	0.0%	30	100.0%
P4_Post * Kelompok	30	100.0%	0	0.0%	30	100.0%
FMA_pre * Kelompok	30	100.0%	0	0.0%	30	100.0%
FMA_post * Kelompok	30	100.0%	0	0.0%	30	100.0%

Report

	Kelompok								
	Perlakuan			Kontrol			Total		
	Mean	Std. Deviation	N	Mean	Std. Deviation	N	Mean	Std. Deviation	N
Cz_Pre	2.7820	2.07190	15	1.3527	.80327	15	2.0673	1.70652	30
Cz_Post	1.5247	.79384	15	1.1827	.66288	15	1.3537	.73933	30
C3_Pre	3.0293	2.61565	15	1.4940	1.37066	15	2.2617	2.19533	30
C3_Post	1.4807	.78689	15	1.1780	.82602	15	1.3293	.80747	30
C4_Pre	2.5953	1.96778	15	1.4173	.90372	15	2.0063	1.61941	30
C4_Post	1.2973	.76844	15	1.3087	.83098	15	1.3030	.78642	30
Pz_Pre	2.7413	2.04382	15	1.4393	.92346	15	2.0903	1.69313	30
Pz_Post	1.3460	.63120	15	1.1847	.76910	15	1.2653	.69615	30
P3_Post	2.6420	2.45416	15	1.3207	1.13699	15	1.9813	1.99580	30
P3_Pre	1.4753	.82108	15	1.0627	.71240	15	1.2690	.78390	30
P4_Pre	2.4667	1.96946	15	1.4833	1.15046	15	1.9750	1.66179	30
P4_Post	1.3327	.78049	15	1.1020	1.04831	15	1.2173	.91563	30
FMA_pre	37.8667	18.36871	15	39.4000	22.87481	15	38.6333	20.39859	30
FMA_post	64.2000	18.25690	15	53.2000	21.88672	15	58.7000	20.57811	30

Hasil Uji Normalitas DTABR dan FMA

Explore Kelompok

Case Processing Summary

	Kelompok	Cases					
		Valid		Missing		Total	
		N	Percent	N	Percent	N	Percent
Cz_Pre	Perlakuan	15	100.0%	0	0.0%	15	100.0%
	Kontrol	15	100.0%	0	0.0%	15	100.0%
Cz_Post	Perlakuan	15	100.0%	0	0.0%	15	100.0%
	Kontrol	15	100.0%	0	0.0%	15	100.0%
C3_Pre	Perlakuan	15	100.0%	0	0.0%	15	100.0%
	Kontrol	15	100.0%	0	0.0%	15	100.0%
C3_Post	Perlakuan	15	100.0%	0	0.0%	15	100.0%
	Kontrol	15	100.0%	0	0.0%	15	100.0%
C4_Pre	Perlakuan	15	100.0%	0	0.0%	15	100.0%
	Kontrol	15	100.0%	0	0.0%	15	100.0%
C4_Post	Perlakuan	15	100.0%	0	0.0%	15	100.0%
	Kontrol	15	100.0%	0	0.0%	15	100.0%
Pz_Pre	Perlakuan	15	100.0%	0	0.0%	15	100.0%
	Kontrol	15	100.0%	0	0.0%	15	100.0%
Pz_Post	Perlakuan	15	100.0%	0	0.0%	15	100.0%
	Kontrol	15	100.0%	0	0.0%	15	100.0%
P3_Post	Perlakuan	15	100.0%	0	0.0%	15	100.0%
	Kontrol	15	100.0%	0	0.0%	15	100.0%
P3_Pre	Perlakuan	15	100.0%	0	0.0%	15	100.0%
	Kontrol	15	100.0%	0	0.0%	15	100.0%
P4_Pre	Perlakuan	15	100.0%	0	0.0%	15	100.0%
	Kontrol	15	100.0%	0	0.0%	15	100.0%
P4_Post	Perlakuan	15	100.0%	0	0.0%	15	100.0%
	Kontrol	15	100.0%	0	0.0%	15	100.0%
FMA_pre	Perlakuan	15	100.0%	0	0.0%	15	100.0%
	Kontrol	15	100.0%	0	0.0%	15	100.0%
FMA_post	Perlakuan	15	100.0%	0	0.0%	15	100.0%
	Kontrol	15	100.0%	0	0.0%	15	100.0%

Tests of Normality

	Kelompok	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
Cz_Pre	Perlakuan	.192	15	.142	.885	15	.056
	Kontrol	.173	15	.200*	.918	15	.180
Cz_Post	Perlakuan	.147	15	.200*	.935	15	.322
	Kontrol	.185	15	.179	.906	15	.117
C3_Pre	Perlakuan	.226	15	.038	.833	15	.010
	Kontrol	.316	15	.000	.712	15	.000
C3_Post	Perlakuan	.123	15	.200*	.952	15	.555
	Kontrol	.252	15	.011	.813	15	.005
C4_Pre	Perlakuan	.210	15	.073	.853	15	.019
	Kontrol	.210	15	.075	.903	15	.107
C4_Post	Perlakuan	.128	15	.200*	.945	15	.448
	Kontrol	.194	15	.132	.895	15	.079
Pz_Pre	Perlakuan	.183	15	.189	.880	15	.048
	Kontrol	.156	15	.200*	.910	15	.135
Pz_Post	Perlakuan	.096	15	.200*	.951	15	.545

	Kontrol	.227	15	.036	.854	15	.020
P3_Post	Perlakuan	.273	15	.004	.749	15	.001
	Kontrol	.264	15	.006	.794	15	.003
P3_Pre	Perlakuan	.162	15	.200*	.933	15	.306
	Kontrol	.228	15	.035	.864	15	.027
P4_Pre	Perlakuan	.272	15	.004	.811	15	.005
	Kontrol	.231	15	.031	.861	15	.025
P4_Post	Perlakuan	.099	15	.200*	.949	15	.515
	Kontrol	.262	15	.007	.835	15	.011
FMA_pre	Perlakuan	.194	15	.132	.882	15	.051
	Kontrol	.159	15	.200*	.924	15	.220
FMA_post	Perlakuan	.185	15	.176	.903	15	.105
	Kontrol	.136	15	.200*	.933	15	.305

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Hasil Uji Wilcoxon DTABR pada Perlakuan

NPar Tests

Wilcoxon Signed Ranks Test

		Ranks		
		N	Mean Rank	Sum of Ranks
Cz_Post - Cz_Pre	Negative Ranks	14 ^a	8.43	118.00
	Positive Ranks	1 ^b	2.00	2.00
	Ties	0 ^c		
C3_Post - C3_Pre	Total	15		
	Negative Ranks	13 ^d	7.85	102.00
	Positive Ranks	1 ^e	3.00	3.00
C4_Post - C4_Pre	Ties	1 ^f		
	Total	15		
	Negative Ranks	13 ^g	9.00	117.00
Pz_Post - Pz_Pre	Positive Ranks	2 ^h	1.50	3.00
	Ties	0 ⁱ		
	Total	15		
P3_Pre - P3_Post	Negative Ranks	14 ^j	7.50	105.00
	Positive Ranks	0 ^k	.00	.00
	Ties	1 ^l		
P4_Post - P4_Pre	Total	15		
	Negative Ranks	12 ^m	8.75	105.00
	Positive Ranks	3 ⁿ	5.00	15.00
P4_Post - P4_Pre	Ties	0 ^o		
	Total	15		
	Negative Ranks	13 ^p	7.00	91.00
P4_Post - P4_Pre	Positive Ranks	0 ^q	.00	.00
	Ties	2 ^r		
	Total	15		

- a. Cz_Post < Cz_Pre
- b. Cz_Post > Cz_Pre
- c. Cz_Post = Cz_Pre
- d. C3_Post < C3_Pre
- e. C3_Post > C3_Pre
- f. C3_Post = C3_Pre
- g. C4_Post < C4_Pre
- h. C4_Post > C4_Pre
- i. C4_Post = C4_Pre
- j. Pz_Post < Pz_Pre
- k. Pz_Post > Pz_Pre
- l. Pz_Post = Pz_Pre
- m. P3_Pre < P3_Post
- n. P3_Pre > P3_Post
- o. P3_Pre = P3_Post
- p. P4_Post < P4_Pre
- q. P4_Post > P4_Pre
- r. P4_Post = P4_Pre

Test Statistics ^a						
	Cz_Post - Cz_Pre	C3_Post - C3_Pre	C4_Post - C4_Pre	Pz_Post - Pz_Pre	P3_Pre - P3_Post	P4_Post - P4_Pre
Z	-3.296 ^b	-3.109 ^b	-3.238 ^b	-3.297 ^b	-2.556 ^b	-3.181 ^b
Asymp. Sig. (2-tailed)	.001	.002	.001	.001	.011	.001

a. Wilcoxon Signed Ranks Test
b. Based on positive ranks.

Wilcoxon Signed Ranks Test

DTABR total kelompok perlakuan

Ranks

		N	Mean Rank	Sum of Ranks
Post test - Pre test	Negative Ranks	15 ^a	8.00	120.00
	Positive Ranks	0 ^b	.00	.00
	Ties	0 ^c		
	Total	15		

- a. Post test < Pre test
- b. Post test > Pre test
- c. Post test = Pre test

Test Statistics^a

Post test - Pre
test

Z	-3.408 ^b
Asymp. Sig. (2-tailed)	.001

Hasil Uji Wilcoxon DTABR pada Kontrol

NPar Tests

Wilcoxon Signed Ranks Test

		Ranks		
		N	Mean Rank	Sum of Ranks
Cz_Post - Cz_Pre	Negative Ranks	9 ^a	8.50	76.50
	Positive Ranks	5 ^b	5.70	28.50
	Ties	1 ^c		
C3_Post - C3_Pre	Total	15		
	Negative Ranks	9 ^d	8.67	78.00
	Positive Ranks	5 ^e	5.40	27.00
C4_Post - C4_Pre	Ties	1 ^f		
	Total	15		
	Negative Ranks	9 ^g	7.78	70.00
Pz_Post - Pz_Pre	Positive Ranks	5 ^h	7.00	35.00
	Ties	1 ⁱ		
	Total	15		
P3_Pre - P3_Post	Negative Ranks	11 ^j	8.23	90.50
	Positive Ranks	3 ^k	4.83	14.50
	Ties	1 ^l		
P4_Post - P4_Pre	Total	15		
	Negative Ranks	10 ^m	9.20	92.00
	Positive Ranks	5 ⁿ	5.60	28.00
P4_Post - P4_Pre	Ties	0 ^o		
	Total	15		
	Negative Ranks	15 ^p	8.00	120.00
P4_Post - P4_Pre	Positive Ranks	0 ^q	.00	.00
	Ties	0 ^r		
	Total	15		

- a. Cz_Post < Cz_Pre
- b. Cz_Post > Cz_Pre
- c. Cz_Post = Cz_Pre
- d. C3_Post < C3_Pre
- e. C3_Post > C3_Pre
- f. C3_Post = C3_Pre
- g. C4_Post < C4_Pre
- h. C4_Post > C4_Pre
- i. C4_Post = C4_Pre
- j. Pz_Post < Pz_Pre
- k. Pz_Post > Pz_Pre
- l. Pz_Post = Pz_Pre
- m. P3_Pre < P3_Post
- n. P3_Pre > P3_Post
- o. P3_Pre = P3_Post
- p. P4_Post < P4_Pre
- q. P4_Post > P4_Pre
- r. P4_Post = P4_Pre

Test Statistics^a

	Cz_Post - Cz_Pre	C3_Post - C3_Pre	C4_Post - C4_Pre	Pz_Post - Pz_Pre	P3_Pre - P3_Post	P4_Post - P4_Pre
Z Asymp. Sig. (2-tailed)	-1.507 ^b .132	-1.602 ^b .109	-1.099 ^b .272	-2.386 ^b .017	-1.818 ^b .069	-3.409 ^b .001

a. Wilcoxon Signed Ranks Test

b. Based on positive ranks.

Wilcoxon Signed Ranks Test

DTABR total kelompok kontrol

Ranks

	N	Mean Rank	Sum of Ranks
Post test - Pre test	Negative Ranks	9 ^a	7.89
	Positive Ranks	4 ^b	5.00
	Ties	2 ^c	
	Total	15	

- a. Post test < Pre test
- b. Post test > Pre test
- c. Post test = Pre test

Test Statistics^a

Post test - Pre
test

Z	-1.783 ^b
Asymp. Sig. (2-tailed)	.075

Mann-Whitney Test

Ranks

	Cz	N	Mean Rank	Sum of Ranks
Hasil Cz	Cz Perlakuan	15	19.67	295.00
	Cz Kontrol	15	11.33	170.00
	Total	30		

Test Statistics^a

Hasil Cz

Mann-Whitney U	50.000
Wilcoxon W	170.000
Z	-2.594
Asymp. Sig. (2-tailed)	.009

Exact Sig. [2*(1-tailed Sig.)]	.009 ^b
--------------------------------	-------------------

a. Grouping Variable: Cz

b. Not corrected for ties.

Mann-Whitney Test

Ranks				
	C3	N	Mean Rank	Sum of Ranks
Hasil C3	C3 Perlakuan	15	19.37	290.50
	C3 Kontrol	15	11.63	174.50
	Total	30		

Test Statistics^a

Hasil C3	
Mann-Whitney U	54.500
Wilcoxon W	174.500
Z	-2.407
Asymp. Sig. (2-tailed)	.016
Exact Sig. [2*(1-tailed Sig.)]	.015 ^b

a. Grouping Variable: C3

b. Not corrected for ties.

Mann-Whitney Test

Ranks				
	C4	N	Mean Rank	Sum of Ranks
Hasil C4	C4 Perlakuan	15	20.70	310.50
	C4 Kontrol	15	10.30	154.50
	Total	30		

Test Statistics^a

Hasil C4	
Mann-Whitney U	34.500
Wilcoxon W	154.500
Z	-3.236
Asymp. Sig. (2-tailed)	.001
Exact Sig. [2*(1-tailed Sig.)]	.001 ^b

- a. Grouping Variable: C4
b. Not corrected for ties.

Mann-Whitney Test

Ranks

	Pz	N	Mean Rank	Sum of Ranks
Hasil Pz	Pz Perlakuan	15	20.03	300.50
	Pz Kontrol	15	10.97	164.50
	Total	30		

Test Statistics^a

Hasil Pz

Mann-Whitney U	44.500
Wilcoxon W	164.500
Z	-2.821
Asymp. Sig. (2-tailed)	.005
Exact Sig. [2*(1-tailed Sig.)]	.004 ^b

- a. Grouping Variable: Pz
b. Not corrected for ties.

Mann-Whitney Test

Ranks

	P3	N	Mean Rank	Sum of Ranks
Hasil P3	P3 Perlakuan	15	18.07	271.00
	P3 Kontrol	15	12.93	194.00
	Total	30		

Test Statistics^a

Hasil P3

Mann-Whitney U	74.000
Wilcoxon W	194.000
Z	-1.597
Asymp. Sig. (2-tailed)	.110
Exact Sig. [2*(1-tailed Sig.)]	.116 ^b

- a. Grouping Variable: P3
 b. Not corrected for ties.

Mann-Whitney Test

Ranks				
P4	N	Mean Rank	Sum of Ranks	
Hasil P4	P4 Perlakuan	15	17.50	262.50
	P4 Kontrol	15	13.50	202.50
	Total	30		

Test Statistics^a

	Hasil P4
Mann-Whitney U	82.500
Wilcoxon W	202.500
Z	-1.245
Asymp. Sig. (2-tailed)	.213
Exact Sig. [2*(1-tailed Sig.)]	.217 ^b

Mann-Whitney Test

DTABRtotal

Ranks				
Kelompok	N	Mean Rank	Sum of Ranks	
Hasil DTABR	Perlakuan	15	20.20	303.00
	Kontrol	15	10.80	162.00
	Total	30		

Test Statistics^a

	Hasil DTABR
Mann-Whitney U	42.000
Wilcoxon W	162.000
Z	-2.925
Asymp. Sig. (2-tailed)	.003
Exact Sig. [2*(1-tailed Sig.)]	.003 ^b

Hasil Uji Wilcoxon FMA pada Perlakuan

NPar Tests Wilcoxon Signed Ranks Test

Ranks

	N	Mean Rank	Sum of Ranks
		.00	.00
	0 ^a		
	15 ^b	8.00	120.00
FMA_post - FMA_pre	Ties	0 ^c	
	Total	15	

- a. FMA_post < FMA_pre
- b. FMA_post > FMA_pre
- c. FMA_post = FMA_pre

Test Statistics^a

	FMA_post - FMA_pre
Z	-3.412 ^b
Asymp. Sig. (2-tailed)	.001

- a. Wilcoxon Signed Ranks Test
- b. Based on negative ranks.

Hasil Uji Wilcoxon FMA pada Kontrol

NPar Tests Wilcoxon Signed Ranks Test

Ranks

	N	Mean Rank	Sum of Ranks
		.00	.00
	0 ^a		
	15 ^b	8.00	120.00
FMA_post - FMA_pre	Ties	0 ^c	
	Total	15	

- a. FMA_post < FMA_pre
- b. FMA_post > FMA_pre
- c. FMA_post = FMA_pre

Test Statistics^a

	FMA_post - FMA_pre
Z	-3.411 ^b
Asymp. Sig. (2-tailed)	.001

- a. Wilcoxon Signed Ranks Test
- b. Based on negative ranks.

Deskriptif FMA (UE, LE, dan Perubahan)

Means

Case Processing Summary

	Cases					
	Included		Excluded		Total	
	N	Percent	N	Percent	N	Percent
FMA_UE.pre * Kelompok	30	100.0%	0	0.0%	30	100.0%
FMA_UE.post *	30	100.0%	0	0.0%	30	100.0%
Kelompok						
FMA_LE.pre * Kelompok	30	100.0%	0	0.0%	30	100.0%
FMA_LE.post * Kelompok	30	100.0%	0	0.0%	30	100.0%

Report

Kelompok		Mean	Std. Deviation	N
Perlakuan	FMA_UE.pre	27.9333	14.44925	15
	FMA_UE.post	44.2667	15.37840	15
	FMA_LE.pre	9.9333	4.13118	15
	FMA_LE.post	19.9333	4.13118	15
Kontrol	FMA_UE.pre	28.0000	16.96635	15
	FMA_UE.post	36.8000	16.30162	15
	FMA_LE.pre	11.4000	6.37854	15
	FMA_LE.post	16.4000	6.17368	15
Total	FMA_UE.pre	27.9667	15.48410	30
	FMA_UE.post	40.5333	16.02742	30
	FMA_LE.pre	10.6667	5.33261	30
	FMA_LE.post	18.1667	5.46515	30

Means

Case Processing Summary

	Cases					
	Included		Excluded		Total	
	N	Percent	N	Percent	N	Percent
Perilaku * FMA	30	100.0%	0	0.0%	30	100.0%
Kontrol * FMA	30	100.0%	0	0.0%	30	100.0%

Report

FMA		Perilaku	Kontrol
Upper	Mean	.4784	.2473
	Std. Deviation	.18616	.15684
	N	15	15
Lower	Mean	.4184	.2336
	Std. Deviation	.12476	.09254
	N	15	15
Total	Mean	.4484	.2404
	Std. Deviation	.15867	.12672
	N	30	30

Hasil Uji Normalitas FMA (UE, LE, dan Perubahan)

Explore Kelompok

Case Processing Summary

	Kelompok	Cases					
		Valid		Missing		Total	
		N	Percent	N	Percent	N	Percent
FMA_UE.pre	Perlakuan	15	100.0%	0	0.0%	15	100.0%
	Kontrol	15	100.0%	0	0.0%	15	100.0%
FMA_UE.post	Perlakuan	15	100.0%	0	0.0%	15	100.0%
	Kontrol	15	100.0%	0	0.0%	15	100.0%
FMA_LE.pre	Perlakuan	15	100.0%	0	0.0%	15	100.0%
	Kontrol	15	100.0%	0	0.0%	15	100.0%
FMA_LE.post	Perlakuan	15	100.0%	0	0.0%	15	100.0%
	Kontrol	15	100.0%	0	0.0%	15	100.0%
Delta_Upper	Perlakuan	15	100.0%	0	0.0%	15	100.0%
	Kontrol	15	100.0%	0	0.0%	15	100.0%
Delta_Lower	Perlakuan	15	100.0%	0	0.0%	15	100.0%
	Kontrol	15	100.0%	0	0.0%	15	100.0%

Tests of Normality

	Kelompok	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
FMA_UE.pre	Perlakuan	.178	15	.200*	.887	15	.061
	Kontrol	.169	15	.200*	.904	15	.109
FMA_UE.post	Perlakuan	.201	15	.107	.836	15	.011
	Kontrol	.181	15	.197	.899	15	.093
FMA_LE.pre	Perlakuan	.225	15	.040	.879	15	.046
	Kontrol	.135	15	.200*	.918	15	.180
FMA_LE.post	Perlakuan	.120	15	.200*	.965	15	.775
	Kontrol	.117	15	.200*	.968	15	.828
Delta_Upper	Perlakuan	.134	15	.200*	.967	15	.807
	Kontrol	.127	15	.200*	.939	15	.373
Delta_Lower	Perlakuan	.129	15	.200*	.971	15	.873
	Kontrol	.159	15	.200*	.970	15	.860

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Deskriptif FMA

Means

Case Processing Summary

	Cases					
	Included		Excluded		Total	
	N	Percent	N	Percent	N	Percent
FMA_pre * Kelompok	30	100.0%	0	0.0%	30	100.0%
FMA_post * Kelompok	30	100.0%	0	0.0%	30	100.0%
delta_FMA * Kelompok	30	100.0%	0	0.0%	30	100.0%

Report

Kelompok		FMA pre	FMA post	delta FMA
Perlakuan	Mean	37.8667	64.2000	-26.3333
	Std. Deviation	18.36871	18.25690	5.21901
	N	15	15	15
Kontrol	Mean	39.4000	53.2000	-13.8000
	Std. Deviation	22.87481	21.88672	6.87854
	N	15	15	15
Total	Mean	38.6333	58.7000	-20.0667
	Std. Deviation	20.39859	20.57811	8.75306
	N	30	30	30

Hasil Uji FMA

NPar Tests Mann-Whitney Test

Ranks					
	Kelompok	N	Mean Rank	Sum of Ranks	
FMA_pre	Perlakuan	15	14.93	224.00	
	Kontrol	15	16.07	241.00	
	Total	30			
FMA_post	Perlakuan	15	18.00	270.00	
	Kontrol	15	13.00	195.00	
	Total	30			
delta_FMA	Perlakuan	15	8.63	129.50	
	Kontrol	15	22.37	335.50	
	Total	30			

Test Statistics^a			
	FMA_pre	FMA_post	delta FMA
Mann-Whitney U	104.000	75.000	9.500
Wilcoxon W	224.000	195.000	129.500
Z	-.354	-1.556	-4.283
Asymp. Sig. (2-tailed)	.724	.120	.000
Exact Sig. [2*(1-tailed Sig.)]	.744 ^b	.126 ^b	.000 ^b

a. Grouping Variable: Kelompok
b. Not corrected for ties.

Hasil Uji Wilcoxon FMA (UE dan LE) Perlakuan

NPar Tests Wilcoxon Signed Ranks Test

Ranks					
		N	Mean Rank	Sum of Ranks	
FMA UE.post - FMA UE.pre	Negative Ranks	0 ^a	.00	.00	
	Positive Ranks	15 ^b	8.00	120.00	
	Ties	0 ^c			
FMA LE.post - FMA LE.pre	Total	15			
	Negative Ranks	0 ^d	.00	.00	
	Positive Ranks	15 ^e	8.00	120.00	
	Ties	0 ^f			
	Total	15			

- a. FMA UE.post < FMA UE.pre
- b. FMA UE.post > FMA UE.pre
- c. FMA UE.post = FMA UE.pre
- d. FMA LE.post < FMA LE.pre
- e. FMA LE.post > FMA LE.pre
- f. FMA LE.post = FMA LE.pre

Test Statistics ^a		
	FMA UE.post - FMA UE.pre	FMA LE.post - FMA LE.pre
Z	-3.418 ^b .001	-3.417 ^b .001
Asymp. Sig. (2-tailed)		

a. Wilcoxon Signed Ranks Test
b. Based on negative ranks.

Hasil Uji Wilcoxon FMA (UE dan LE) Kontrol

NPar Tests Wilcoxon Signed Ranks Test

		Ranks		
		N	Mean Rank	Sum of Ranks
FMA UE.post - FMA UE.pre	Negative Ranks	0 ^a	.00	.00
	Positive Ranks	15 ^b	8.00	120.00
	Ties	0 ^c		
	Total	15		
	Negative Ranks	0 ^d	.00	.00
	Positive Ranks	15 ^e	8.00	120.00
FMA LE.post - FMA LE.pre	Ties	0 ^f		
	Total	15		

- a. FMA UE.post < FMA UE.pre
- b. FMA UE.post > FMA UE.pre
- c. FMA UE.post = FMA UE.pre
- d. FMA LE.post < FMA LE.pre
- e. FMA LE.post > FMA LE.pre
- f. FMA LE.post = FMA LE.pre

Test Statistics ^a		
	FMA UE.post - FMA UE.pre	FMA LE.post - FMA LE.pre
Z	-3.414 ^b .001	-3.433 ^b .001
Asymp. Sig. (2-tailed)		

a. Wilcoxon Signed Ranks Test
b. Based on negative ranks.

Hasil Uji Mann Whitney Perubahan FMA Antara Upper dan Lower

NPar Tests Mann-Whitney Test

Ranks

	FMA	N	Mean Rank	Sum of Ranks
Perilaku	Upper	15	17.13	257.00
	Lower	15	13.87	208.00
	Total	30		
Kontrol	Upper	15	15.40	231.00
	Lower	15	15.60	234.00
	Total	30		

Test Statistics^a

	Perilaku	Kontrol
Mann-Whitney U	88.000	111.000
Wilcoxon W	208.000	231.000
Z	-1.016	-.062
Asymp. Sig. (2-tailed)	.309	.950
Exact Sig. [2*(1-tailed Sig.)]	.325 ^b	.967 ^b

a. Grouping Variable: FMA

b. Not corrected for ties.

Hasil Uji Mann Whitney Upper dan Lower Antara Perilaku dan Kontrol

NPar Tests Mann-Whitney Test

Ranks

	Kelompok	N	Mean Rank	Sum of Ranks
Delta_Upper	Perlakuan	15	20.40	306.00
	Kontrol	15	10.60	159.00
	Total	30		
Delta_Lower	Perlakuan	15	21.43	321.50
	Kontrol	15	9.57	143.50
	Total	30		

Test Statistics^a

	Delta Upper	Delta Lower
Mann-Whitney U	39.000	23.500
Wilcoxon W	159.000	143.500
Z	-3.049	-3.693
Asymp. Sig. (2-tailed)	.002	.000
Exact Sig. [2*(1-tailed Sig.)]	.002 ^b	.000 ^b

a. Grouping Variable: Kelompok

b. Not corrected for ties.